Related Experiment Video
Updated: May 8, 2026

Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics
Published on: November 30, 2012
Minoxidil sulfate induced the increase in blood-brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling
Yan-ting Gu1, Yi-xue Xue2, Yan-feng Wang3
1Department of Physiology, Life Science and Biology Pharmacopedia Institution, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning Province, PR China.
Abstract:
Adenosine 5'-triphosphate-sensitive potassium channel (KATP channel) activator, minoxidil sulfate (MS), can selectively increase the permeability of the blood-tumor barrier (BTB); however, the mechanism by which this occurs is still under investigation. Using a rat brain glioma (C6) model, we first examined the expression levels of occludin and claudin-5 at different time points after intracarotid infusion of MS (30 μg/kg/min) by western blotting. Compared to MS treatment for 0 min group, the protein expression levels of occludin and claudin-5 in brain tumor tissue of rats showed no changes within 1 h and began to decrease significantly after 2 h of MS infusion. Based on these findings, we then used an in vitro BTB model and selective inhibitors of diverse signaling pathways to investigate whether reactive oxygen species (ROS)/RhoA/PI3K/PKB pathway play a key role in the process of the increase of BTB permeability induced by MS. The inhibitor of ROS or RhoA or PI3K or PKB significantly attenuated the expression of tight junction (TJ) protein and the increase of the BTB permeability after 2 h of MS treatment. In addition, the significant increases in RhoA activity and PKB phosphorylation after MS administration were observed, which were partly inhibited by N-2-mercaptopropionyl glycine (MPG) or C3 exoenzyme or LY294002 pretreatment. The present study indicates that the activation of signaling cascades involving ROS/RhoA/PI3K/PKB in BTB was required for the increase of BTB permeability induced by MS. Taken together, all of these results suggested that MS might increase BTB permeability in a time-dependent manner by down-regulating TJ protein expression and this effect could be related to ROS/RhoA/PI3K/PKB signal pathway.
Insights
Minoxidil sulfate (MS) increases blood-tumor barrier (BTB) permeability by downregulating tight junction proteins. This effect involves the ROS/RhoA/PI3K/PKB signaling pathway in a time-dependent manner.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Minoxidil sulfate (MS), a potassium channel activator, is known to enhance blood-tumor barrier (BTB) permeability.
- The precise molecular mechanisms underlying MS-induced BTB permeability changes remain incompletely understood.
Purpose of the Study:
- To elucidate the time-dependent effects of MS on BTB permeability.
- To investigate the involvement of the reactive oxygen species (ROS)/RhoA/PI3K/PKB signaling pathway in MS-mediated BTB alterations.
Main Methods:
- Utilized a rat brain glioma (C6) model and an in vitro BTB model.
- Assessed occludin and claudin-5 expression via western blotting at various time points post-MS infusion.
- Employed selective pathway inhibitors (ROS, RhoA, PI3K, PKB) and measured RhoA activity and PKB phosphorylation.
Main Results:
- MS infusion led to a significant decrease in occludin and claudin-5 expression starting 2 hours post-administration.
- Inhibition of ROS, RhoA, PI3K, or PKB attenuated MS-induced BTB permeability increase and tight junction protein downregulation.
- MS administration increased RhoA activity and PKB phosphorylation, partially reversible by MPG, C3 exoenzyme, or LY294002.
Conclusions:
- MS increases BTB permeability in a time-dependent manner, associated with decreased tight junction protein expression.
- The ROS/RhoA/PI3K/PKB signaling pathway is crucial for MS-induced BTB permeability enhancement.
- These findings provide mechanistic insights into MS's effects on the brain tumor microenvironment.
More Related Videos
Related Concept Videos
The Blood-brain Barrier
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

